Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors
| Autor: | Jagdeep S. Walia, John Underwood, Gillian T. Sleep, Makoto Yoshimitsu, Vanessa I. Rasaiah, Armando G. Poeppl, Takeya Sato, Gary J. Murray, Lori J. West, Jeffrey A. Medin, Roscoe O. Brady, Kesheng Tao |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Genetic enhancement
Transgene Genetic Vectors Globotriaosylceramide Enzyme-Linked Immunosorbent Assay Spleen Biology Cell Line Viral vector Mice chemistry.chemical_compound Immune system medicine Animals Humans Luciferase Transgenes Chromatography High Pressure Liquid Multidisciplinary Lentivirus Biological Sciences medicine.disease Immunohistochemistry Fabry disease medicine.anatomical_structure Animals Newborn chemistry Immunology Fabry Disease |
| Zdroj: | Proceedings of the National Academy of Sciences. 101:16909-16914 |
| ISSN: | 1091-6490 0027-8424 |
| DOI: | 10.1073/pnas.0407572101 |
| Popis: | Successful therapy for many inherited disorders could be improved if the intervention were initiated early. This is especially true for lysosomal storage disorders. Earlier intervention may allow metabolic correction to occur before lipid buildup has irreversible consequences and/or before the immune system mounts limiting responses. We have been developing gene therapy to treat lysosomal storage disorders, especially Fabry disease. We describe studies directed toward metabolic correction in neonatal animals mediated by recombinant lentiviral vectors. To develop this method, we first injected a marking lentiviral vector that engineers expression of luciferase into the temporal vein of recipient neonatal animals. The use of a cooled charged-coupled device camera allowed us to track transgene expression over time in live animals. We observed intense luciferase expression in many tissues, including the brain, that did not diminish over 24 weeks. Next, we injected neonatal Fabry mice a single time with a therapeutic lentiviral vector engineered to express human α-galactosidase A. The injection procedure was well tolerated. We observed increased plasma levels of α-galactosidase A activity starting at our first plasma collection point (4 weeks). Levels of α-galactosidase A activity were found to be significantly elevated in many tissues even after 28 weeks. No immune response was observed against the corrective transgene product. Increased levels of enzyme activity also led to significant reduction of globotriaosylceramide in the liver, spleen, and heart. This approach provides a method to treat lysosomal storage disorders and other disorders before destructive manifestations occur. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|